Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Comment periods extended

This article was originally published in The Gray Sheet

Executive Summary

Comment period on proposed call for premarket approval applications for saline-filled breast implants has been extended by 30 days to April 8, according to a March 10 Federal Register notice. FDA also plans to extend the comment period on its proposed call for testicular prosthesis PMAs to May 14; FDA initially planned to accept comments on the testicular implant proposal until March 15. Mentor petitioned FDA to extend both comment periods to July 10 ("The Gray Sheet" March 1, In Brief).

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel